BrightGene seeks a partner for Zepbound-beating obesity shot

Elizabeth Cairns

Senior biopharma journalist

A Shanghai-based biotech, previously known as a generics and manufacturing player, posted mid-stage results suggesting its incretin drug might be one of the most powerful …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BrightGene seeks a partner for Zepbound-beating obesity shot

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Kymera inks deal with Gilead as partnership with Sanofi faces a switch-up

Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say

FDA investigating Sarepta’s Duchenne gene therapy following patient deaths

Bayer's stem cell group BlueRock restructures pipeline, lays off staffers

Acting CDER chief is leaving after almost nine years at FDA

Digital Twins in GMP Manufacturing: Shaping the Future of CPV with Aizon

Bright­Gene seeks a part­ner for Zep­bound-beat­ing obe­si­ty shot

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Kymera inks deal with Gilead as part­ner­ship with Sanofi faces a switch-up

Ex­clu­sive: FDA's Makary sought re­jec­tion of KalVista’s drug in an un­usu­al move by com­mis­sion­er, sources say

FDA in­ves­ti­gat­ing Sarep­ta’s Duchenne gene ther­a­py fol­low­ing pa­tient deaths

Bay­er's stem cell group Blue­Rock re­struc­tures pipeline, lays off staffers

Act­ing CDER chief is leav­ing af­ter al­most nine years at FDA

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

BrightGene seeks a partner for Zepbound-beating obesity shot

Kymera inks deal with Gilead as partnership with Sanofi faces a switch-up

Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say

FDA investigating Sarepta’s Duchenne gene therapy following patient deaths

Bayer's stem cell group BlueRock restructures pipeline, lays off staffers

Acting CDER chief is leaving after almost nine years at FDA

Digital Twins in GMP Manufacturing: Shaping the Future of CPV with Aizon